口蹄疫疫苗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Foot and Mouth Disease Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月26日 | 出版商:

Global Market Insights Inc. | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球口蹄疫 (FMD) 疫苗市场价值为 25 亿美元，预测显示出成长轨迹，预计 2024 年至 2032 年复合年增长率为 7.7%。政府实体采取积极措施以及畜产品商业化蓬勃发展。

口蹄疫 (FMD) 是一种病毒感染，具有高度传染性，影响猪、牛、山羊和绵羊等动物。此病毒属于小核糖核酸病毒科，会出现发烧、口腔、脚部、偶尔在乳头上出现水泡等症状。口蹄疫在全球的广泛流行是市场扩张的关键驱动力。例如，世界动物卫生组织 2023 年的资料强调，口蹄疫病毒存在于全球约 77% 的牲畜族群中，特别是在非洲、中东、亚洲和南美洲等地区。

有鑑于口蹄疫对牲畜健康、农业生产力和经济稳定的深远影响，全球各国政府正在加强口蹄疫疫苗接种力度。这些努力旨在提高疫苗的可及性，确保广泛的免疫接种，并促进口蹄疫控制和根除方面的国际合作。例如，2022年8月，昆士兰州政府拨款2,000万美元加强其FMD防御战略。

整个产业分为疫苗类型、动物类型、配销通路和地区。

市场将疫苗分为常规疫苗和紧急疫苗。传统疫苗又进一步分为氢氧化铝疫苗、皂苷疫苗和油疫苗。 2023年，传统疫苗以83.9%的份额占据市场主导地位。几个关键因素推动了对传统口蹄疫疫苗的需求。影响偶蹄动物的口蹄疫可能会对畜牧业造成严重的经济影响，包括生产力下降、贸易限制和广泛的控制措施。

口蹄疫疫苗依动物种类分为牛、绵羊和山羊、猪等。 2023 年，牛类市场的估值为14 亿美元，引领市场。严重症状。

2023 年，北美 FMD 疫苗市值为 7.034 亿美元，预计到 2032 年复合年增长率为 6.7%。由于口蹄疫疫情对牲畜和农业经济带来严重风险，人们更加关注预防策略。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Biogenesis Bago
Biovet Private Ltd
Brilliant Bio Pharma Private Limited
BVI
C.H. Boehringer Sohn AG and Co. KG
Ceva Sante Animale
Indian Immunologicals Ltd.
Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
Kenya Veterinary Vaccines Production Institute
Merck and Co., Inc.
MEVAC

简介目录

Product Code: 11014

The Global Foot and Mouth Disease (FMD) vaccines market was valued at USD 2.5 billion in 2023, with projections indicating a growth trajectory, with an anticipated CAGR of 7.7% from 2024 to 2032. This growth is largely fueled by the increasing frequency of FMD outbreaks, proactive measures by government entities, and a booming livestock product commercialization.

Foot and mouth disease (FMD) is a viral infection, highly contagious, impacting animals like pigs, cattle, goats, and sheep. The virus, part of the Picornaviridae family, presents symptoms, such as fever and blisters in the mouth, on the feet, and occasionally on the teats. The widespread prevalence of FMD globally is a key driver for the market expansion. For example, data from the World Organization for Animal Health in 2023 highlighted that the FMD virus is present in about 77% of the global livestock population, notably in regions like Africa, the Middle East, Asia, and South America.

Recognizing the profound effects of FMD on livestock health, agricultural productivity, and economic stability, governments globally are ramping up their FMD vaccination initiatives. These efforts aim to enhance vaccine accessibility, ensure widespread immunization, and promote international collaboration for FMD control and eradication. For instance, in August 2022, Queensland's government allocated USD 20 million to strengthen its FMD defense strategies.

The overall industry is segmented into vaccine type, animal type, distribution channel, and region.

The market segments vaccines into conventional and emergency types. Within conventional vaccines, there is a further division into aluminium hydroxide and saponin-based and oil-based. In 2023, conventional vaccines dominated the market with an 83.9% share. Several pivotal factors drive the demand for conventional FMD vaccines. FMD, affecting cloven-hoofed animals, can lead to severe economic repercussions in the livestock sector, including reduced productivity, trade limitations, and extensive control measures.

Vaccines for FMD are categorized based on the animal type into cattle, sheep and goats, pigs, and others. The cattle segment led the market with a valuation of USD 1.4 billion in 2023. Being primary hosts for the virus, cattle show heightened susceptibility to FMD, often manifesting severe symptoms like fever, lameness, and characteristic vesicles on their feet, mouth, and teats.

North America FMD vaccines market was valued at USD 703.4 million in 2023, with projections indicating a 6.7% CAGR through 2032. The rising adoption of FMD vaccines underscores a commitment to protecting livestock and the broader agricultural sector from this viral threat. With FMD outbreaks posing severe risks to livestock and the agricultural economy, there is an intensified focus on preventive strategies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising research and development activities for animal healthcare
  - 3.2.1.2 Frequent FMD outbreaks
  - 3.2.1.3 Government initiatives and regulations
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.7 New emerging therapies
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Conventional vaccines
- 5.2.1 Aluminium hydroxide and saponin-based vaccines
- 5.2.2 Oil-based vaccines
5.3 Emergency vaccines

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cattle
6.3 Sheep and Goat
6.4 Pig
6.5 Other animals

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Veterinary hospitals and clinics
7.3 Government institutions
7.4 Retail pharmacies
7.5 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa